You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)首批復必泰疫苗運抵台灣
阿思達克 09-03 10:40
復星醫藥(02196.HK)表示,由BioNTech(BNTX.US)生產、供應台灣地區的新冠疫苗復必泰(BNT162)從歐洲運抵台灣桃園機場,首批到貨93.2萬劑。該款疫苗將通過台灣地區民間機構捐贈途徑,適用於12歲以上青少年及成人的主動免疫接種,以預防由新型冠狀病毒感染引起的疾病。 復星醫藥董事長兼首席執行官吳以芳表示,很高興看到這款由復星醫藥和BioNTech共同合作的mRNA新冠疫苗,能助力台灣建立新冠免疫屏障。 復星醫藥控股子公司復星實業(香港)於7月份與台積電(TSM.US)、鴻海、永齡基金會、慈濟基金會及裕利醫藥簽訂共計1,500萬劑mRNA新冠疫苗的銷售協議。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account